Atea Pharmaceuticals, Inc. (AVIR)

Atea Pharmaceuticals’ preliminary results showed EPS of -$0.41 topping the -$0.56 estimate by $0.15 for the second fiscal quarter of 2026, reported August 12, 2026, alongside a net loss that narrowed year over year. Net income was a loss of about $32.9 million, up ~11% from a loss of roughly $37.2 million a year ago, while operating income came in at a loss of about $35.1 million. On a per-share basis, EPS improved ~7% from -$0.44 a year ago. The company generated negative operating cash flow of about $37.1 million during the quarter. Atea remains focused on advancing its antiviral pipeline, including bemnifosbuvir and ruzasvir programs in hepatitis C. For the next period, consensus calls for EPS of -$0.51 on revenue of $50.4 million.